Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

NCT05545800 on ClinicalTrials.gov · last registry update 2022-09-19

A small phase 3 — 78 participants, against a typical 424. Its estimated completion date, 1 June 2024, has passed with no update to the record. Primary outcome, as filed: Mean Change From Baseline in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Xiangya Hospital of Central South University
Sponsor type: Other
Enrollment: 78
Started: 2022-09-01
Primary completion: 2024-06-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Baseline in HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.